Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 5/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5527658 | 0.84 | P2RY14 (0.34) | NT5EDUTP2RY14P2RY12CYP3A4 | |
| SCHEMBL8042949 | 0.79 | NT5E (0.35) | NT5ETYMPDUTP2RY14CYP3A4 | |
| SCHEMBL5531485 | 0.79 | SLC28A1 (0.40) | P2RY12P2RY2P2RY4 | |
| SCHEMBL4074082 | 0.79 | SLC28A1 (0.40) | P2RY12P2RY2P2RY4 | |
| SCHEMBL4083099 | 0.79 | SLC28A1 (0.40) | P2RY12P2RY2P2RY4 | |
| SCHEMBL4083526 | 0.79 | SLC28A1 (0.40) | P2RY12P2RY2P2RY4 | |
| SCHEMBL5978909 | 0.79 | TYMP (0.42) | NT5ETYMPDUTP2RY14CYP3A4 | |
| SCHEMBL4081765 | 0.78 | TK2 (0.43) | NT5ETYMPP2RY14P2RY12P2RY2 | |
| SCHEMBL6419737 | 0.78 | TYMP (0.42) | NT5ETYMPDUTP2RY14CYP3A4 | |
| SCHEMBL31467672 | 0.77 | TYMP (0.45) | NT5ETYMPDUTP2RY14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507859-B2 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC (US) | 2009-03-24 | — | — | US | disclosed |
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | ANXA6, STING1, POLRMT | NT5E 887/4885TYMP 2413/4885DUT 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.